Calculated Whole Blood Viscosity and Albumin/Fibrinogen Ratio in Patients with a New Diagnosis of Multiple Myeloma: Relationships with Some Prognostic Predictors

Background: In this single center study, we retrospectively evaluated the calculated hemorheological profile in patients with a new diagnosis of multiple myeloma, with the aim to evaluate possible relationships with some prognostic predictors, such as ISS, albumin levels, beta2-microglobulin, red cell distribution width, and bone marrow plasma cell infiltration. Methods: In a cohort of 190 patients, we examined the calculated blood viscosity using the de Simone formula, and the albumin/fibrinogen ratio as a surrogate of erythrocyte aggregation, and then we related these parameters to prognostic factors, using the Kruskal–Wallis and the Mann–Whitney tests, respectively. Results: From our analysis, it emerged that the evaluated hemorheological pattern differed in the three isotypes of multiple myeloma, and the whole blood viscosity was higher in IgA and IgG isotypes with respect to the light chain multiple myeloma (p < 0.001). Moreover, we observed that, as the ISS stage progressed, the albumin/fibrinogen ratio was reduced, and the same hemorheological trend was traced in subgroups with lower albumin levels, higher beta2-microglobulin and red cell distribution width RDW values, and in the presence of a greater bone marrow plasma cell infiltrate. Conclusions: Through the changes in blood viscosity in relation to different prognostic factors, this analysis might underline the role of the hemorheological pattern in multiple myeloma.

[1]  G. Caimi,et al.  Erythrocyte deformability profile evaluated by laser diffractometry in patients with multiple myeloma: Re-examination of our cases. , 2022, Microvascular research.

[2]  Min Zhou,et al.  Application of clinical nomograms to predicting overall survival and event-free survival in multiple myeloma patients: Visualization tools for prognostic stratification , 2022, Frontiers in Public Health.

[3]  J. Suh,et al.  Red Blood Cell Deformability and Distribution Width in Patients with Hematologic Neoplasms. , 2022, Clinical laboratory.

[4]  Jiayue Liu,et al.  Is RDW a clinically relevant prognostic factor for newly diagnosed multiple myeloma? A systematic review and meta-analysis , 2022, BMC cancer.

[5]  Tracy Holloway King,et al.  Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR) , 2022, British journal of haematology.

[6]  G. Castellani,et al.  Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. D'Agostino,et al.  Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting , 2022, Frontiers in Oncology.

[8]  A. Kraśniak,et al.  The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment , 2022, Medicina.

[9]  A. Titov,et al.  Knowns and Unknowns about CAR-T Cell Dysfunction , 2022, Cancers.

[10]  Yu Hu,et al.  Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma. , 2021, International immunopharmacology.

[11]  G. Caimi,et al.  Comparison between whole blood viscosity measured and calculated in subjects with monoclonal gammopathy of undetermined significance and in patients with multiple myeloma: Re-evaluation of our survey. , 2021, Clinical hemorheology and microcirculation.

[12]  G. Caimi,et al.  Reflections on the unexpected laboratory finding of hemorheological alterations observed in some haematological disorders. , 2021, Microvascular research.

[13]  J. Roliński,et al.  Immunological Prognostic Factors in Multiple Myeloma , 2021, International journal of molecular sciences.

[14]  D. Dingli,et al.  Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. , 2020, Clinical lymphoma, myeloma & leukemia.

[15]  H. Dürr,et al.  Tumor load in patients with multiple myeloma: β₂‐microglobulin levels versus low‐dose whole‐body CT , 2019, European journal of haematology.

[16]  N. Mishra,et al.  Blood Viscosity, Glycemic Markers and Blood Pressure: A Study in Middle-Aged Normotensive and Hypertensive Type 2 Diabetics , 2018, Indian Journal of Clinical Biochemistry.

[17]  Peipei Xu,et al.  Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[18]  Yu Hu,et al.  Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis , 2018, Cancer Cell International.

[19]  G. Caimi,et al.  Erythrocyte deformability and hemorheological profile in multiple myeloma. , 2017, Clinical hemorheology and microcirculation.

[20]  G. Caimi,et al.  Red blood cell deformability in multiple myeloma1. , 2018, Clinical hemorheology and microcirculation.

[21]  P. Julia,et al.  Serum Hepcidin Levels in Multiple Myeloma. , 2017, Clinical laboratory.

[22]  Jie Jin,et al.  Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases , 2017, Hematology.

[23]  M. Aljurf,et al.  The Evolution of Prognostic Factors in Multiple Myeloma , 2017, Advances in hematology.

[24]  S. Hasić,et al.  Dilemma: Correlation Between Serum Level of Hepcidin and IL-6 in Anemic Myeloma Patients , 2016, Medical archives.

[25]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[26]  H. Goldschmidt,et al.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Vangsted,et al.  Causes of early death in multiple myeloma patients who are ineligible for high‐dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database , 2015, American journal of hematology.

[28]  Hong Liu,et al.  Hepcidin and GDF15 in anemia of multiple myeloma , 2014, International Journal of Hematology.

[29]  H. Goldschmidt,et al.  IMWG consensus on risk stratification in multiple myeloma , 2014, Leukemia.

[30]  S. Vincent Rajkumar,et al.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.

[31]  Neelima Singh,et al.  Blood Viscosity, Lipid Profile, and Lipid Peroxidation in Type-1 Diabetic Patients with Good and Poor Glycemic Control , 2013, North American journal of medical sciences.

[32]  K. Patel,et al.  Association of the red cell distribution width with red blood cell deformability. , 2013, Advances in experimental medicine and biology.

[33]  H. Kwaan Hyperviscosity in plasma cell dyscrasias. , 2013, Clinical hemorheology and microcirculation.

[34]  S. Ševčíková,et al.  Prognostic significance of morphological assessment of plasma cells in multiple myeloma. , 2011, Neoplasma.

[35]  D. Rossi,et al.  Beta‐2‐microglobulin is an independent predictor of progression in asymptomatic multiple myeloma , 2010, Cancer.

[36]  Sang-We Kim,et al.  Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma , 2010, Annals of Hematology.

[37]  B. Barlogie,et al.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.

[38]  D. Meyerstein,et al.  A novel technique for quantification of erythrocyte aggregation abnormalities in pathophysiological situations. , 2007, Clinical hemorheology and microcirculation.

[39]  O. Baskurt,et al.  Hemodynamic effects of red blood cell aggregation. , 2007, Indian journal of experimental biology.

[40]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  V. Lauta,et al.  A review of the cytokine network in multiple myeloma , 2003, Cancer.

[42]  Terry L. Smith,et al.  High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. , 1991, Annals of internal medicine.

[43]  M. C. Magalhães,et al.  Hypoalbuminemia in patients with multiple myeloma. , 1990, Archives of internal medicine.

[44]  S Chien,et al.  Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. , 1990, Circulation.

[45]  M. Jourdan,et al.  Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. , 1989, The Journal of clinical investigation.

[46]  Dr H. Oakervee Myeloma , 2002, Lyon medical.

[47]  E. Merrill,et al.  Yield stress of normal human blood as a function of endogenous fibrinogen. , 1969, Journal of applied physiology.

[48]  L. Langstroth BLOOD VISCOSITY , 1919, The Journal of experimental medicine.